2015
DOI: 10.15690/pf.v12i5.1461
|View full text |Cite
|
Sign up to set email alerts
|

New Aspects of Genetic Basis, Classification and Treatment of Osteogenesis Imperfecta: Literature Review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
1
0
1

Year Published

2019
2019
2022
2022

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 44 publications
0
1
0
1
Order By: Relevance
“…The types do not go from mildest to most severe. This classification system has been generally accepted world wide since 1979 OI continues to evolve as new information is discovered (Yakhyayeva et al, 2015b). Later this classification was supplemented by M. Ramachandran et al (Pigarova et al, 2017), which also took into account the violation of dentinogenesis, OI the IV type of OI was subdivided into subtype B, which is accompanied by defects of dentinogenesis, and subtype A, which does not have these violations.…”
Section: Evolution Of Classification Criteria Of Osteogenesis Imperfectamentioning
confidence: 99%
“…The types do not go from mildest to most severe. This classification system has been generally accepted world wide since 1979 OI continues to evolve as new information is discovered (Yakhyayeva et al, 2015b). Later this classification was supplemented by M. Ramachandran et al (Pigarova et al, 2017), which also took into account the violation of dentinogenesis, OI the IV type of OI was subdivided into subtype B, which is accompanied by defects of dentinogenesis, and subtype A, which does not have these violations.…”
Section: Evolution Of Classification Criteria Of Osteogenesis Imperfectamentioning
confidence: 99%
“…В настоящее время имеются данные об эффективности применения деносумаба у пациентов с описанным типом заболевания, который действует на остеокласты посредством иного механизма: через ингибирование системы RANK/RANKL/остеопротегерин препарат предотвращает созревание и активацию остеокластов до того, как они адгезируются на костном матриксе [32]. Этот терапевтический эффект характеризуется независимостью от состояния минерализации кости, объясняя наблюдение, описанное ранее, что деносумаб более эффективно снижает резорбцию кости у пациентов с НО VI типа, чем бисфосфонаты [15,33].…”
Section: клинический случай о пациентеunclassified